2. Pregnancy causes SLE to exacerbate3. 3. Pregnancy causes SLE to remit4. 4 . The answer is unknown.
Even at the end of 1992, with hundreds of lupus pregnancies now reported, there is no consensus regarding the relationship between lupus and pregnancy. The lack of consensus is attributable in part to different intake criteria for patients in different clinics, in part to demographic differences among these patients, and in part to different ways investigators identify flare. Different lupus clinics see very different populations. The differences among clinics begin with ethnicity. In American studies there is wide variation in the proportion of lupus patients who are Afro-American (black).
While there is controversy whether Afro-American women have a different lupus experience than do American women of European origin (white), there is no debate that there are important socio-economic differences between blacks and whites or that hypertension, which can seriously compromise a pregnancy, is commoner in the former group'. In white majority populations the term 'black' generally includes persons of mixed race even though persons of mixed race share characteristics of both races. Despite evidence to the contrary6, in studies of lupus Afro-Americans are often considered to be genetically homogeneous but Euro-Americans are not. No pregnancy study has addressed in depth the role of ethnic diversity.
Greater differences among studies result from the mechanisms by which pregnant lupus patients are entered into a study. Many lupus pregnancy clinics known to the author, including his own, attract referrals from a population base that grew after the clinic's interest in pregnancy management became well known.
This referral base is not the same as the referral base for lupus uncomplicated by pregnancy, and two important effects that bias conclusions result. Firstly, because its denominator is different, the regular (non-pregnancy) lupus clinic becomes an invalid comparison group. Secondly, the reason for the pregnancy referral may influence the result of the study. An example is that our own clinic disproportionately (compared to other clinics) attracted SLE women with antiphospholipid antibodies and recurrent pregnancy loss. Many of our patients were seen after a recent loss for planning for the next pregnancy. Most of our patients were in clinical remission, and our flare rate during the next pregnancy was quite low. Another clinic's patients were first referred, pregnant, with active disease. Almost none had antiphospholipid antibodies, and the flare rate was high'.
The different flare rates in the two clinics can be attributed to the different reasons for referral. Table I outlines study design differences for recent papers on lupus flare rate during pregnancy. The table also points out when a woman is studied during more than one pregnancy. This is inappropriate study design because, since clinical events of successive pregnancies tend to repeat one another, her course biases the conclusions about the population at large to the extent that she appears more than once. Finally, the table notes when investigators include patients first diagnosed to have lupus during the index pregnancy. This is also a flaw of study design. It causes an overestimation of flare rates, since, by definition, an asymptomatic patient cannot be Studies also differ regarding whether flare is diagnosed -on the basis of a predetermined scale or on the basis of a global assessment of the treating physician. Modern flare scales are better tools, and investigators who employ more than one scale have more credible studies. Scales are imperfect, however, since even within a scale clinical gestalt-read investigator prejudicedistinguishes between, for instance, pregnancy-and lupus-induced thrombocytopenia or proteinuria. Investigators to date have not employed independent blinded arbiters of flare and thus cannot escape the fact that they may have tilted their conclusions in one direction or another by personal judgement about when a flare has occurred.
Concatenation of lupus flare is another investigator gestalt that is seldom discussed. When is it fair to say that a patient has had a continuous, though fluctuating, flare and when has she had two flares in short succession? The question seems trivial, but some studies allow the counting of multiple flares per pregnancy and others only one flare per pregnancy. The calculated flare rates differ accordingly. , ~°W hat constitutes a quantitatively sufficient amount of disease to-score flare present or absent? Accepting dayto-day variation of lupus activity . for which patients make small changes in their maintenance prednisone dose as the norm, our studies ignored disease activity changes that resulted in prescription changes of < 10 mg prednisone/day, i.e. accepted only 'clinically meaningful' flares'. Other studies counted as flares increases in disease activity that led to no changes of corticosteroid dose, i.e. maximized the count beyond any response the physician might make'. There is no gold standard for this judgement, but some differences among studies are attributable to such preset cut-offs for labeling a flare present or absent. So, do lupus patients flare during pregnancy? According to our own figures, the risk is between 1 in 4 and 1 in 9 (liberal versus conservative flare criteria) that a woman will have a treatable flare during pregnancy, and this risk is the same as that of a matched non-pregnant patient group','. According to Petri, the risk is 1 in 1.65, approximately thrice that of selfor unmatched controls, but many of these flares need no treatment'.
Urowitz believes that women with active disease at onset of pregnancy stay active, and that women with inactive disease are protected by pregnancy~.
Thus, the available literature offers only contradic-tions regarding whether pregnancy induces flare, and the answer to the question that started this paper is (4), the answer is unknown.
What to do? In this correspondent's opinion, clinics must predefine and combine data and stratify for race and for reason for referral. Published flare rates per pregnancy vary over a six-fold range. With the published numbers, even in an unstratified population at least 50-100 women (with an identical number of pregnancies) and their matched controls will required to answer whether pregnancy causes lupus to flare. Because of referral bias, studies based on closed populations of lupus patients will be more valuable than will studies on referred populations. Algorithms for defining flare must be agreed by the investigators at the outset of the study, as must the basic treatment options.
Given that some authors believe the risk to be low, that other authors who believe the risk to be high do not always recommend treatment, and that conservative treatment of flare in pregnancy does not differ from conservative treatment when a woman is not pregnant, the best advice at this time is to monitor all pregnant lupus patients carefully, and to prescribe no prophylactic therapy for flare. Definitive answers await studies yet to be published.
